Quantcast

Latest Thrombosis Stories

2014-02-26 23:02:53

The Firm is investigating testosterone treatment lawsuits on behalf of men who suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism, or other serious cardiovascular problems, allegedly due to AndroGel and other low testosterone therapies. New York, NY (PRWEB) February 26, 2014 As testosterone lawsuits (http://www.testosteronelawsuitcenter.com/ ) involving AndroGel continue to mount, Bernstein Liebhard LLP notes that a leading consumer advocacy group is pushing...

2014-02-19 23:02:44

The Firm is evaluating testosterone treatment lawsuits on behalf of individuals who allegedly suffered heart attacks, strokes, deep vein thrombosis, and pulmonary embolism due to their use of prescription “Low T” therapies like AndroGel. New York, New York (PRWEB) February 19, 2014 Testosterone treatment lawsuits (http://www.testosteronelawsuitcenter.com/) involving prescription medications like AndroGel continue to mount in courts throughout the country, Bernstein Liebhard LLP...

2014-02-14 08:26:09

RARITAN, N.J., Feb. 14, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) issued complete response letters (CRLs) regarding supplemental New Drug Applications (sNDAs) for the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of secondary cardiovascular events - defined as heart attack, stroke or death - in patients with acute coronary syndrome (ACS) and to reduce the risk of stent...

2014-01-08 12:30:25

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO and PARSIPPANY, N.J., Jan. 8, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the New Drug Application (NDA) for its investigational, oral, once-daily direct factor Xa-inhibitor SAVAYSA(TM) (edoxaban) Tablets has been submitted to the U.S. Food...

2014-01-07 12:28:27

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO and MUNICH, Jan. 7, 2014 /PRNewswire/ -- Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application (MAA) for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency...

2013-12-18 23:28:27

National network of lawyers will continue offer of these consultations through Christmas and New Year’s Day. Allegations being reviewed include migrations, perforation, filter fracture and other problems linked by FDA to life-threatening health problems. San Diego, CA (PRWEB) December 18, 2013 http://www.resource4thepeople.com/defectivemedicaldevices/bard-ivc.html Resource4thePeople announced today that its national network of attorneys will be available over the upcoming holiday...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related